Ambulatory Care Self-Assessment Program (ACSAP) Book 2: Women's and Men's Health (Cert # L249209)

The target audience Ambulatory Care Self-Assessment Program (ACSAP)  Book 2: Women's and Men's Health is board-certified and advanced level ambulatory care clinical pharmacists.

Board certified pharmacists are eligible to receive up to 16 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.  

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP are approved by BPS as a provider for the recertification of BCACP.

Women's and Men's Health I
ACPE #: 0217-9999-24-159-H01-P

Drug Therapy Considerations in Pregnancy and Lactation

• Distinguish the regulatory responsibilities between drug manufacturers and pharmacists regarding medication use in pregnancy and lactation.
• Classify the physiologic phases of pregnancy and lactation to predict potential impacts on drug pharmacokinetics and pharmacodynamics.
• Assess a drug’s potential for teratogenicity based on fetal physiology and the drug’s pharmacokinetic properties.
• Design an appropriate regimen and monitoring plan for a drug prescribed to a lactating parent based on patient factors and drug characteristics. 
• Judge the fetal safety of a therapeutic regimen in a pregnant patient using drug information from different resources. 

Endometriosis

• Evaluate risk factors and diagnostic criteria for endometriosis and design an appropriate approach to treatment.
• Distinguish between treatment approaches according to recent guideline updates and patient’s desire for fertility.
• Develop an initial treatment plan for endometriosis-related pain management based on patient-specific factors and adjust based on changing clinical picture.
• Develop an initial adjunctive medication treatment plan for endometriosis-related infertility based on patient-specific factors and adjust based on changing clinical picture.
• Design a monitoring plan for a patient with endometriosis-related pain including adjustments based on suboptimal response and in different clinical scenarios 

Women's and Men's Health II
ACPE #: 0217-9999-24-160-H01-P

Benign Prostatic Hyperplasia

• Evaluate the risk factors associated with benign prostatic hyperplasia (BPH).
• Assess results of the diagnostic evaluation of BPH in order to determine which cases can be managed medically.
• Design a plan for medical management of BPH, including lifestyle modifications and pharmacotherapy, on the basis of patient-specific factors.
• Classify the various minimally invasive and surgical treatments available for BPH.
• Design an assessment and treatment plan for complications associated with BPH. 

Urinary Incontinence and Bladder Dysfunction

• Classify the differences in and risk factors for urinary incontinence (UI) and/or bladder dysfunction types.
• Compose a treatment plan including pharmacologic and nonpharmacologic modalities for UI/bladder dysfunction based on diagnosis and patient-specific factors.
• Apply guideline recommendations and updated literature to evaluate the treatment hierarchy for stress UI and overactive bladder.
• Evaluate treatment options for assessment and management of UI/bladder dysfunction for special populations. 

Women's and Men's Health III
ACPE #: 0217-9999-24-161-H01-P

Sex-Specific Cancers

• Devise appropriate patient counseling points on the basis of identifying modifiable risk factors for sex-specific cancers.
• Assess differences in screening between individuals at high risk and those at average risk.
• Evaluate differences between medication-related risk factors and their risk of sex-specific cancers.
• Produce a plan for screening recommendations for sex-specific cancer on the basis of patient-specific factors.
• Justify human papillomavirus (HPV) vaccinations for all pertinent populations.
• Distinguish between adverse effect profiles for tamoxifen and raloxifene and aromatase inhibitors. 

Sex and Gender Effects in Pharmacokinetics and Pharmacodynamics

• Evaluate the role of sex-related and gender-related effects on the risk and progression of common chronic health conditions.
• Demonstrate how sex-related and gender-related effects extend to medication therapy management for transgender and gender-diverse people.
• Evaluate sex-related and gender-related effects in medication absorption, distribution, metabolism, and excretion.
• Analyze clinically significant sex-related and gender-related effects on medication therapy safety and effectiveness. 

Women's and Men's Health IV
ACPE #: 0217-9999-24-162-H01-P

Case Series: Medication Management for Pregnancy Termination

• Evaluate the benefits and limitations of medication management of pregnancy loss.
• Design an appropriate medication regimen for pregnancy loss or termination.
• Develop monitoring parameters and patient education for an individual using medications for the management of pregnancy loss or termination.
• Assess the implications of state and federal laws on access to medications used in the treatment of pregnancy loss. 

Case Series: Treatment of Male Osteoporosis

• Distinguish the differences between the drug therapy recommendations from practice guidelines and recent trials for the treatment of male osteoporosis.
• Assess appropriate screening recommendations related to male osteoporosis.
• Assess the mechanism of action, efficacy, and safety of bisphosphonates and denosumab therapies for the treatment of male osteoporosis, and explain how they compare with other antiresorptive and anabolic agents used to treat osteoporosis.
• Justify the role of anabolic therapy in the treatment of male osteoporosis.
• Assess appropriate lifestyle modifications for the treatment of male osteoporosis.
• Evaluate common secondary causes of male osteoporosis. 

Case Series: Contraception Updates and Implementation of Pharmacist Prescribing

• Evaluate the landscape and provision of contraception in the United States, including novel contraception methods or indications, their place in therapy, and accessibility in pharmacies.
• Analyze barriers and potential solutions to implement pharmacist-prescribed contraception services.
• Design a patient-specific plan for hormonal contraception based on the individual’s history, preferences, and eligibility.
• Analyze communication strategies regarding how to discuss the advantages and disadvantages of the various methods of contraception with an individual.
• Design a patient-specific plan for hormonal contraception for patients belonging to special populations, including lesbian, gay, bisexual, transgender, queer, and adolescent populations.

Faculty Information

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

Consultancies: Michael P. Kane (Novo Nordisk); Kristen Lamberjack (Oscar Insurance)

Stock Ownership: Kelly K. Houck (Eli Lilly; Pfizer)

Honoraria: Michael P. Kane (Novo Nordisk)

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

• Complete the attestation statement
• Review all content
• Complete and pass the assessments
• Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on ambulatory care pharmacy activities.